Advisory engagements for every stage.

Your investors will find the gaps. The question is whether you find them first. Most founders don't know what's sitting in their blind spot until they're already in a data room and the deal is starting to unravel. By then it's too late to fix it cleanly.

A 2–3 week deep dive across your clinical protocols, data infrastructure, regulatory exposure and cap table structure. We go looking for the things that slow fundraising, complicate acquisitions and give investors a reason to reprice or walk. You get a clear picture of where you stand and a prioritised roadmap for what to address first. No surprises. No generic recommendations. Just honest clarity from people who have been on both sides of the table.

Walking into investor meetings without the right foundations is the fastest way to lose a deal you spent years building toward. Sophisticated investors and acquirers are not just buying your product. They are buying the business around it. The governance, the compliance posture, the financial controls, the clinical evidence. If those aren't in order, the conversation stalls or the terms get punishing.

We build the full investor-grade architecture. Governance documentation. Clinical evidence packages. Compliance roadmaps. Financial controls. By the time you're in the room, you're not hoping they don't find anything. You already know they won't.

A strong clinical product doesn't automatically translate into a scalable business. We help founders build the commercial architecture — pricing, channels, revenue operations and expansion sequencing — that turns product momentum into predictable revenue.

This is for ventures that have proof of concept and now need to get to market with discipline: the right segments, the right partnerships, and a commercial model that investors can underwrite.